Follow us on

MyCartis news

The latest developments in personalising healthcare. This is what’s happening in the world of MyCartis.

10 November 2014

MyCartis at Medica

MyCartis is exhibiting the Evalution™ platform at Medica. Meet us in hall 3, booth K32.

the MyCartis

About MyCartis
Let’s make
healthcare personal

The big revolution in healthcare today is that we are finally realizing that we are all equal, but not identical, certainly not at a molecular level. So why do we still use the ‘One size fits all’-model in healthcare? MyCartis is convinced that our healthcare system needs radical change and that the future lies in personalization. Our ultimate goal is to identify the right therapy for the right patient at the right time and location with the right dose.

So how are we going to change healthcare? By being at the forefront of innovation and personalisation. By sharing knowledge and expertise with like-minded organisations and partners. On our road to validate biomarkers on a larger scale, we are building a bridge between research and medical practice. We will improve healthcare for future generations by making it more efficient and more effective.

We aim to change healthcare all over the world by making it personal.


MyCartis technologies: accelerate innovation

MyCartis constantly develops technologies that push healthcare towards the next level of personalization. Not by ourselves, but by being part of a bigger network where we share ideas, knowledge and expertise. This allows us to accelerate innovation.

> Evalution™

MyCartis applications: improve bioassays

MyCartis is committed to provide disruptive solutions in the fields of clinical and translational research for its customers and partners. By making biomarker assays simpler and faster, healthcare is already becoming more personalised.

> Biomarkers

Evalution™ - the multiplexed analysis of biomarkers made fast and simple

Accelerate your research, trust your results
Evalution™ is MyCartis’ multiplex analysis platform tailored to the development of clinical biomarkers. It has been designed to analyze a broad range of protein and nucleic- acid based biomarkers to delivers high quality data and rapid results from minimal handling steps with unprecedented ease. Evalution™ integrates into a single instrument all the functions of incubation, washing, and optical readout for seamless operation of sophisticated assay protocols. The combination of customizable encoded microparticles with microfluidic assay plates in Evalution™ enables the combined analysis of protein and nucleic-acid biomarkers simultaneously. The platform Evalution is intended for research use only – Not for diagnostic procedure

> More Evalution™

MyCartis biomarker innovations

Protocols have been developed that enable a large variety of applications for the detection of proteins and nucleic acids such as sandwich immunoassays, (auto) antibody assays, genotyping, mutation analysis, m(i)RNA profiling. Novel proprietary biomarkers are in a late stage of protein biomarker pipeline and dedicated panels are in development for their validation. In parallel MyCartis is also developing research kits for a number of disease areas as part of it’s product pipeline.

> Biomarker innovations
> Solutions

Our partners in the healthcare revolution

Changing healthcare is not something we do on our own. MyCartis strongly believes in co-creation. By sharing ideas, knowledge, and expertise with our selected partners we realise our joint ambition of improving healthcare for future generations. Right now we are looking for new partners to accelerate the personalisation of healthcare.

> Find out more